Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 4522

  • The following term was not found in PubMed: 68636.
1.

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.

Saunders KO, Wiehe K, Tian M, Acharya P, Bradley T, Alam SM, Go EP, Scearce R, Sutherland L, Henderson R, Hsu AL, Borgnia MJ, Chen H, Lu X, Wu NR, Watts B, Jiang C, Easterhoff D, Cheng HL, McGovern K, Waddicor P, Chapdelaine-Williams A, Eaton A, Zhang J, Rountree W, Verkoczy L, Tomai M, Lewis MG, Desaire HR, Edwards RJ, Cain DW, Bonsignori M, Montefiori D, Alt FW, Haynes BF.

Science. 2019 Dec 6;366(6470). pii: eaay7199. doi: 10.1126/science.aay7199. No abstract available.

PMID:
31806786
2.

Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy.

Pardons M, Fromentin R, Pagliuzza A, Routy JP, Chomont N.

Cell Rep. 2019 Nov 26;29(9):2783-2795.e5. doi: 10.1016/j.celrep.2019.10.101.

3.

An MPER antibody neutralizes HIV-1 using germline features shared among donors.

Zhang L, Irimia A, He L, Landais E, Rantalainen K, Leaman DP, Vollbrecht T, Stano A, Sands DI, Kim AS; IAVI Protocol G Investigators, Poignard P, Burton DR, Murrell B, Ward AB, Zhu J, Wilson IA, Zwick MB.

Nat Commun. 2019 Nov 26;10(1):5389. doi: 10.1038/s41467-019-12973-1.

4.

Getting to Zero San Francisco: A Collective Impact Approach.

Buchbinder SP, Havlir DV.

J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3:S176-S182. doi: 10.1097/QAI.0000000000002200.

PMID:
31764252
5.

Subclinical cardiovascular disease in HIV controller and long-term nonprogressor populations.

Brusca RM, Hanna DB, Wada NI, Blankson JN, Witt MD, Jacobson LP, Kingsley L, Palella FJ Jr, Budoff M, Brown TT, Anastos K, Lazar JM, Mack WJ, Bacchetti P, Tien PC, Golzar Y, Plankey M, Golub E, Kaplan RC, Post WS.

HIV Med. 2019 Nov 14. doi: 10.1111/hiv.12820. [Epub ahead of print]

PMID:
31729142
6.

De novo and inherited variants in ZNF292 underlie a neurodevelopmental disorder with features of autism spectrum disorder.

Mirzaa GM, Chong JX, Piton A, Popp B, Foss K, Guo H, Harripaul R, Xia K, Scheck J, Aldinger KA, Sajan SA, Tang S, Bonneau D, Beck A, White J, Mahida S, Harris J, Smith-Hicks C, Hoyer J, Zweier C, Reis A, Thiel CT, Jamra RA, Zeid N, Yang A, Farach LS, Walsh L, Payne K, Rohena L, Velinov M, Ziegler A, Schaefer E, Gatinois V, Geneviève D, Simon MEH, Kohler J, Rotenberg J, Wheeler P, Larson A, Ernst ME, Akman CI, Westman R, Blanchet P, Schillaci LA, Vincent-Delorme C, Gripp KW, Mattioli F, Guyader GL, Gerard B, Mathieu-Dramard M, Morin G, Sasanfar R, Ayub M, Vasli N, Yang S, Person R, Monaghan KG, Nickerson DA, van Binsbergen E, Enns GM, Dries AM, Rowe LJ, Tsai ACH, Svihovec S, Friedman J, Agha Z, Qamar R, Rodan LH, Martinez-Agosto J, Ockeloen CW, Vincent M, Sunderland WJ, Bernstein JA; Undiagnosed Diseases Network,, Eichler EE, Vincent JB; University of Washington Center for Mendelian Genomics (UW-CMG),, Bamshad MJ.

Genet Med. 2019 Nov 14. doi: 10.1038/s41436-019-0693-9. [Epub ahead of print]

PMID:
31723249
7.

Machine learning to identify persons at high-risk of HIV acquisition in rural Kenya and Uganda.

Balzer LB, Havlir DV, Kamya MR, Chamie G, Charlebois ED, Clark TD, Koss CA, Kwarisiima D, Ayieko J, Sang N, Kabami J, Atukunda M, Jain V, Camlin CS, Cohen CR, Bukusi EA, van der Laan M, Petersen ML.

Clin Infect Dis. 2019 Nov 7. pii: ciz1096. doi: 10.1093/cid/ciz1096. [Epub ahead of print]

PMID:
31697383
8.

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.

Steichen JM, Lin YC, Havenar-Daughton C, Pecetta S, Ozorowski G, Willis JR, Toy L, Sok D, Liguori A, Kratochvil S, Torres JL, Kalyuzhniy O, Melzi E, Kulp DW, Raemisch S, Hu X, Bernard SM, Georgeson E, Phelps N, Adachi Y, Kubitz M, Landais E, Umotoy J, Robinson A, Briney B, Wilson IA, Burton DR, Ward AB, Crotty S, Batista FD, Schief WR.

Science. 2019 Dec 6;366(6470). pii: eaax4380. doi: 10.1126/science.aax4380. Epub 2019 Oct 31.

PMID:
31672916
9.

Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore.

Hackman J, Falade-Nwulia O, Patel EU, Mehta SH, Kirk GD, Astemborski J, Ray SC, Thomas DL, Laeyendecker O.

Infect Genet Evol. 2019 Oct 24;77:104078. doi: 10.1016/j.meegid.2019.104078. [Epub ahead of print]

10.

Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR-/- Mice.

Larocca RA, Mendes EA, Abbink P, Peterson RL, Martinot AJ, Iampietro MJ, Kang ZH, Aid M, Kirilova M, Jacob-Dolan C, Tostanoski L, Borducchi EN, De La Barrera RA, Barouch DH.

Cell Host Microbe. 2019 Nov 13;26(5):591-600.e4. doi: 10.1016/j.chom.2019.10.001. Epub 2019 Oct 24.

PMID:
31668877
11.

Recent Trends and Effectiveness of Antiretroviral Regimens Among Men Who Have Sex With Men Living With HIV in the United States: The Multicenter AIDS Cohort Study (MACS) 2008-2017.

Li X, Brown TT, Ho KS, Witt MD, Phair J, Jacobson LP.

Open Forum Infect Dis. 2019 Jul 16;6(9):ofz333. doi: 10.1093/ofid/ofz333. eCollection 2019 Sep.

12.

The Mid-Atlantic Center for AIDS Research Consortium Scholars Program: A Multi-Institutional Approach to Mentoring the Next Generation of Underrepresented Scientists.

Limaye RJ, Magnus M, Metzger D, Blank MB, Davis W, Celentano DD; Mid-Atlantic Center for AIDS Research Consortium.

J Acquir Immune Defic Syndr. 2019 Dec 1;82 Suppl 2:S124-S127. doi: 10.1097/QAI.0000000000002171.

13.

Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence.

Brault MA, Spiegelman D, Hargreaves J, Nash D, Vermund SH.

J Acquir Immune Defic Syndr. 2019 Dec 1;82 Suppl 2:S104-S112. doi: 10.1097/QAI.0000000000002168.

14.

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.

Clarke DF, Mirochnick M, Acosta EP, Capparelli E, Chain A, Teppler H, Smith B, Lommerse J; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1110 Study Team.

J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):392-398. doi: 10.1097/QAI.0000000000002149.

PMID:
31658182
15.

Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression.

Musinguzi N, Castillo-Mancilla J, Morrow M, Byakwaga H, Mawhinney S, Burdo TH, Boum Y, Muzoora C, Bwana BM, Siedner MJ, Martin JN, Hunt PW, Bangsberg DR, Haberer JE.

J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):386-391. doi: 10.1097/QAI.0000000000002148.

PMID:
31658181
16.

Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs).

Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, Valente P, Greene GJ, Sherman SG, Footer KHA, D'Aquila RT, Carballo-Diéguez A, Hope TJ.

AIDS Behav. 2019 Oct 25. doi: 10.1007/s10461-019-02703-5. [Epub ahead of print]

PMID:
31654172
17.

Role of IL-15 Signaling in the Pathogenesis of Simian Immunodeficiency Virus Infection in Rhesus Macaques.

Okoye AA, DeGottardi MQ, Fukazawa Y, Vaidya M, Abana CO, Konfe AL, Fachko DN, Duell DM, Li H, Lum R, Gao L, Park BS, Skalsky RL, Lewis AD, Axthelm MK, Lifson JD, Wong SW, Picker LJ.

J Immunol. 2019 Dec 1;203(11):2928-2943. doi: 10.4049/jimmunol.1900792. Epub 2019 Oct 25.

PMID:
31653683
18.

Cognitive Development of Infants Exposed to the Zika Virus in Puerto Rico.

Valdes V, Zorrilla CD, Gabard-Durnam L, Muler-Mendez N, Rahman ZI, Rivera D, Nelson CA 3rd.

JAMA Netw Open. 2019 Oct 2;2(10):e1914061. doi: 10.1001/jamanetworkopen.2019.14061.

19.

Predictors of Viremia in Postpartum Women on Antiretroviral Therapy.

Hoffman RM, Warshaw MG, Amico KR, Pilotto J, Masheto G, Achalapong J, Machado E, Chokephaibulkit K, Duarte G, João E, Graham KK, Knapp KM, Stek AM, Scott GB, Coletti A, Loftis AJ, Chakhtoura N, Currier JS; PROMISE 1077HS Team.

J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):72-80. doi: 10.1097/QAI.0000000000002228.

PMID:
31651545
20.

Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).

Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, Pathak S, Bekker LG, Swaminathan S, Stanton J, Farrior J, Sista N.

J Int AIDS Soc. 2019 Oct;22(10):e25408. doi: 10.1002/jia2.25408.

Supplemental Content

Loading ...
Support Center